Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of Thursday, August 20, 2026.
EBITDA YIELD
N/A
Market Cap
$10.50B
EBITDA Yield
5.00%
TTM Avg
14.28%
3Y Avg
12.12%
5Y Avg
10.51%
Market Cap
$10.43B
EBITDA Yield
17.48%
TTM Avg
15.10%
3Y Avg
12.75%
5Y Avg
12.56%
Market Cap
$11.35B
EBITDA Yield
3.07%
TTM Avg
2.45%
3Y Avg
2.90%
5Y Avg
2.75%
Market Cap
$9.80B
EBITDA Yield
3.66%
TTM Avg
4.71%
3Y Avg
5.17%
5Y Avg
4.76%
Market Cap
$11.68B
EBITDA Yield
6.63%
TTM Avg
7.21%
3Y Avg
5.56%
5Y Avg
4.85%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $10.73B | N/A | N/A | N/A | N/A |
| Molina Healthcare, Inc. (MOH)vs › | $10.50B | 5.00% | 14.28% | 12.12% | 10.51% |
| Insulet Corp. (PODD)vs › | $10.49B | 5.69% | 3.54% | 2.43% | 1.75% |
| Universal Health Services, Inc. (UHS)vs › | $10.43B | 17.48% | 15.10% | 12.75% | 12.56% |
| Henry Schein, Inc. (HSIC)vs › | $10.17B | 7.84% | 8.67% | 8.48% | 8.64% |
| Bio-Techne Corporation (TECH)vs › | $11.35B | 3.07% | 2.45% | 2.90% | 2.75% |
| DaVita Inc. (DVA)vs › | $11.38B | 12.92% | 11.27% | 11.02% | 10.95% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.80B | 3.66% | 4.71% | 5.17% | 4.76% |
| Align Technology, Inc. (ALGN)vs › | $11.68B | 6.63% | 7.21% | 5.56% | 4.85% |
| Oscar Health, Inc. (OSCR)vs › | $8.37B | 9.16% | 2.25% | 3.18% | 3.18% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
